Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

CAPS Rating: 2 out of 5

A biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions.

Results 1 - 20 of 38 : 1 2 Next »

Recs

1
Member Avatar Tophinater (38.78) Submitted: 10/24/2014 10:13:29 AM : Outperform Start Price: $187.36 ALXN Score: -6.70

Sure, why not?

Recs

0
Member Avatar pchop123 (80.31) Submitted: 7/13/2014 6:55:12 PM : Outperform Start Price: $164.32 ALXN Score: +8.62

upside in price very likely

Recs

1
Member Avatar BigFatBEAR (29.16) Submitted: 7/9/2014 4:22:34 PM : Outperform Start Price: $161.62 ALXN Score: +9.23

Too rich for my real cash at this level, but loved enough by informed folks, such as zzlangerhans, to make me a watcher. Low beta, which could be quite handy in a selloff, but I'm guessing this thing will kiss $100 someday in the next year or two, what with biotech being volatile and all.

Appears to be one of the best-of-breed in the sector, so if you're going to own individual stocks instead of IBB, might as well go this route.

Recs

0
Member Avatar poluh2k (52.41) Submitted: 6/9/2014 8:44:39 AM : Underperform Start Price: $170.02 ALXN Score: -3.57

p/e 103
p/s 12
p/fcf 89
not good for long and not bad for short

Recs

0
Member Avatar SnowBawl (< 20) Submitted: 5/5/2014 9:35:59 AM : Outperform Start Price: $155.11 ALXN Score: +9.29

13 classic growth stocks (Sterman).

Recs

0
Member Avatar TerryFool (42.37) Submitted: 3/7/2014 10:51:40 AM : Outperform Start Price: $164.85 ALXN Score: +2.96

BUY@ 165 1YR EPS 130% 2YR EPS 200% TP 188

Recs

0
Member Avatar Dudeone (94.42) Submitted: 2/12/2014 6:35:18 PM : Outperform Start Price: $174.23 ALXN Score: -7.65

Soliris continuing to grow and good products in pipeline e.g. asfotase

Recs

0
Member Avatar billyw10 (< 20) Submitted: 1/3/2014 6:26:30 PM : Outperform Start Price: $131.66 ALXN Score: +28.79

orphan drug alxn

Recs

1
Member Avatar TerryHoodSr (61.55) Submitted: 5/29/2013 2:41:47 PM : Outperform Start Price: $93.87 ALXN Score: +72.06

3yr rev growth 36%

Recs

0
Member Avatar CarlosDK (20.52) Submitted: 1/10/2013 8:12:04 AM : Underperform Start Price: $100.68 ALXN Score: -44.16

expensive on all valuations

Recs

0
Member Avatar ayuddha (33.29) Submitted: 7/15/2012 5:18:50 PM : Outperform Start Price: $96.87 ALXN Score: +39.64

It was picked by www.hechtsoft.de Trade Alerts.

Recs

1
Member Avatar danrifenburgh (< 20) Submitted: 12/19/2011 1:25:55 PM : Outperform Start Price: $67.44 ALXN Score: +105.80

After a 60% run-up, this volatile stock seems due for a fall. TM P/E of 82.96 with expected earnings growth of 31.54% taking it to a forward P/E of 38.81 next year. ALXN also trades at a premium to S&P500 TTM P/E. The PEG stands at 2.24, this could suggest some overvaluation. The Price/Book is 11.62.

Recs

1
Member Avatar rannici (< 20) Submitted: 10/27/2011 9:24:45 AM : Outperform Start Price: $67.84 ALXN Score: +113.05

just following the trend...

Recs

1
Member Avatar tradingblues1 (63.32) Submitted: 10/13/2011 7:05:08 PM : Outperform Start Price: $68.08 ALXN Score: +104.41

soaring to the moon!!

Recs

0
Member Avatar SIDRWC (77.47) Submitted: 9/28/2011 2:50:23 AM : Outperform Start Price: $67.62 ALXN Score: +100.29

The long-term potential growth for this company is astronomical... They seem to have incredible moment at this point, and is closely linked to stock-market turbulence. Very excited for this companies potential, and am buying in for the long hall.

Recs

0
Member Avatar phatchips767 (< 20) Submitted: 7/25/2011 11:36:06 AM : Outperform Start Price: $58.67 ALXN Score: +164.05

ibd

Recs

0
Member Avatar mrindependent (35.86) Submitted: 11/24/2010 1:30:43 PM : Underperform Start Price: $38.21 ALXN Score: -317.27

Found this stock with a screen that looks for stocks that are stratospherically valued based on high expectations. CAPS score of 2 is higher than expected, which indicates that somebody likes this stock at this price. The deciding factor for me was the negative commentary from ZZLangerhans.

Recs

0
Member Avatar CramersSkeeDaddy (98.22) Submitted: 10/13/2010 12:01:39 PM : Outperform Start Price: $34.08 ALXN Score: +373.75

biotech spec 3

Recs

1
Member Avatar Witchdoctor78 (52.85) Submitted: 9/11/2010 10:06:30 PM : Outperform Start Price: $30.46 ALXN Score: +430.36

Upcommimg biotech with a first in class drug due to expand its fda indications. They have pricing power, an off the beaten path pipeline, international presence and good marketing reach in the US. They face no competition for their indications, think Genzyme, only more focused. Could be an acquisition too.

Recs

0
Member Avatar jbs4radio (71.85) Submitted: 6/26/2009 1:19:38 AM : Outperform Start Price: $22.46 ALXN Score: +632.18

Russell 2000 long term growth 31-173%

Results 1 - 20 of 38 : 1 2 Next »

Featured Broker Partners


Advertisement